Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
Century Health Raises $5M Seed Round as AI-Powered Platform Achieves 97% Accuracy in Clinical Data Abstraction
Century Health has raised an oversubscribed $5 million seed round to expand…
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
The FDA has accepted Roche’s supplemental application for Gazyva/Gazyvaro as a treatment…
GSK completes acquisition of 35Pharma Inc.
GSK plc has completed the acquisition of 35Pharma Inc., adding HS235, a…
GSK to Acquire RAPT Therapeutics, Advancing Long-Acting IgE Therapy for Food Allergy Patients
GSK has agreed to acquire RAPT Therapeutics, adding a long-acting anti-IgE therapy…
FDA Grants Breakthrough Therapy Designation to Novartis’ Ianalumab for Sjögren’s Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s…
Saudi Dermatology Society and Novartis Saudi Partner to Enhance Chronic Urticaria Care Across the Kingdom
SSDDS and Novartis Saudi have entered a strategic partnership to enhance medical…
Understanding Inflammatory Bowel Disease (IBD) with Dr. Hussam Saleh: Symptoms, Myths & Treatments
Dr. Saleh provided crucial insights into this chronic condition, emphasizing the importance…
GSK Partners with Hengrui Pharma to Advance COPD and Oncology Drug Pipeline
GSK plc announced it has entered into agreements with Hengrui Pharma to…
